Cardiovascular risk after COPD exacerbations in NZ and the role of triple therapy
Session Date:
COPD exacerbations markedly elevate short- and medium-term cardiovascular risk. In this session, Professor Jeff Harrison and Dr William Good review New Zealand real‑world data on post‑exacerbation CV events and examine whether inhaled triple therapy (ICS/LABA/LAMA) offers cardioprotective benefits beyond exacerbation reduction, with practical takeaways for clinical practice.
This breakfast session is sponsored by:
in partnership with
